Endometrial Adenocarcinoma

P2, N=102, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2024 --> Mar 2025

Finally, adhesion assays with trophoblast-derived AC-1M-88 spheroids were used to examine the effects of substrate stiffness and steroid hormones on endometrial receptivity. We conclude that the extracellular matrix and hormones act together to determine mechanical properties and, ultimately, embryo implantation.

P2, N=288, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Apr 2024 --> Dec 2024

P2, N=349, Active, not recruiting, National Cancer Institute (NCI)

Our study demonstrates that an aggressive disease like a high-grade adenocarcinoma of the endometrium inflicts the pro-metastatic event of LVSI by involving the immune landscape of both tumor and TME. This study demonstrates, for the first time, that the tumor cells within LVSI are positive for IL-12R-B2 and S100A4.

P=N/A, N=1400, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025

The tumor was invasive and extended beyond one-half of the muscle layer with a high degree of vascular invasion. In conclusion, we need to focus on the various shapes of the cell aggregate, nuclear grooves, and intranuclear pseudo-inclusions of tumor cells to distinguish an ML-EAC from other endometrial carcinomas in endometrial cytology.

The results suggest that the combined use of p16 and Rb IHC could be a reliable method to predict HR-HPV infection in primary ECAs and mimics. This finding may contribute to prognostic prediction and therapeutic strategy.

P3, N=188, Recruiting, University of Utah | Active, not recruiting --> Recruiting | N=108 --> 188 | Trial completion date: Sep 2024 --> Oct 2029 | Trial primary completion date: Dec 2021 --> Nov 2026

This case illustrates that new FOXL2 mutations may be detected in ovarian sex cord-stromal tumors with increasing use of routine molecular testing, adding to the complexity of the pathologic diagnosis. In the right morphologic and clinical context, a FOXL2 mutation-even if it is different from the dominant hotspot mutation c.402C>G (p.C134W)-can support the diagnosis of adult granulosa cell tumor.

P2, N=10, Not yet recruiting, Queensland Centre for Gynaecological Cancer

P1, N=15, Active, not recruiting, University of Colorado, Denver | Trial completion date: Nov 2023 --> Nov 2024

P1, N=60, Active, not recruiting, NeoTX Therapeutics Ltd. | Phase classification: P1b --> P1 | Trial completion date: Aug 2025 --> Oct 2026 | Trial primary completion date: May 2025 --> Oct 2026

P1, N=60, Recruiting, National Cancer Institute (NCI) | Initiation date: May 2024 --> Dec 2023

P1/2, N=159, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024

P1/2, N=72, Active, not recruiting, Centre Leon Berard | Trial completion date: Dec 2023 --> Dec 2024

Long-term androgen use may have unknown implications for the development of malignancy, and treating reproductive organ cancer in transgender males may be complicated by the desire to continue androgen therapy.

P1, N=24, Recruiting, Neogene Therapeutics, Inc. | Not yet recruiting --> Recruiting

P2, N=80, Recruiting, Roswell Park Cancer Institute | Not yet recruiting --> Recruiting

Cytoplasmic HuR expression is a poor prognosis marker in endometrioid endometrial adenocarcinoma, while cytoplasmic methyl-HuR and nuclear phosphoHuR expressions are markers of better prognosis. This study highlights HuR as a promising potential therapeutic target, especially in treatment-resistant tumors, though further research is needed to understand the mechanisms regulating HuR subcellular localization and post-translational modifications.

P1, N=34, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=77 --> 34

P1, N=24, Not yet recruiting, Neogene Therapeutics, Inc.

P2, N=28, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting

In this retrospective study, obesity is associated with increased rates of disease control and improved PFS in patients treated with pembrolizumab for recurrent or advanced MMRd/MSI-H endometrial adenocarcinomas.

In EEAs, this study proposed a broad molecular signature of CRLs are promising biomarkers for predicting clinical outcomes and therapeutic responses.

P1, N=60, Recruiting, National Cancer Institute (NCI) | Phase classification: P1b --> P1

P3, N=48, Completed, Women's Cancer Care Associates, LLC | Active, not recruiting --> Completed | N=450 --> 48

Furin is associated with the development and progression of EAC through the induction of proliferation, invasion, and metastasis of malignant cells of EAC. Furin induces ontogenesis in EAC through activation expression of ADAM17, pro-renin receptor, CD109, and TGF-β. As well, EAC-mediated inflammation promotes the expression of furin with further propagation of neoplastic growth and invasion.

Novel candidate genetic variants that might contribute to endometriosis were suggested that need replication through independent cohorts or validation by functional studies. The family has also received genetic counseling and that the affected daughters are on clinical follow-up, accordingly.

Secondary rectal cancer with endometrial origination in the absence of endometriosis and serosal implants was extremely rare. Therefore, we should pay more attention to this rare but possible presentation for appropriate diagnosis and treatment of these patients.

P1, N=12, Recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024

Functional investigation of this inversion in a laboratory setting revealed a resultant abnormal protein function. Thus, we have identified an unusual, small germline inversion in a mismatch repair gene that does not lead to a premature stop codon yet appears likely to be causal for the observed cancers.

P1/2, N=390, Recruiting, Acrivon Therapeutics | Phase classification: P1b/2 --> P1/2

P1b, N=60, Active, not recruiting, NeoTX Therapeutics Ltd. | Trial completion date: Aug 2023 --> Aug 2025 | Trial primary completion date: May 2023 --> May 2025

These results suggested that the localization of the Bcl-2 family protein observed under E-induced apoptosis is related to the malignancy of endometrial cancer cells. We hope that the dynamics of Bcl-2 family proteins such as Bcl-X and Bad will be used to diagnose malignant endometrial adenocarcinomas.

P1, N=50, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2023 --> Oct 2024

Because of a specific p.G12C-KRAS somatic mutation, only the minority of MLA (7.9% with uterine and 6.2% with ovarian primary) are potentially targetable by sotarasib in that rare but aggressive subtype of adenocarcinoma of the female genital tract. Until now, the different location of a somatic KRAS-mutation is of no prognostic impact.

Of 1099 patients included in this study, 45 (4.1%) patients were enrolled in a trial. 31 (68.9%) of those who were enrolled in a clinical trial had undergone CGP, compared to 14 (31.1%) who had not undergone CGP (p <0.001). Those who had CGP were more likely to be enrolled in a clinical trial compared to those who did not have CGP (OR 13.55, CI 5.82 - 31.56).

Complete cytoreduction seemed favorable with a mean survival of 32 months in contrast to 10 months when complete cytoreduction was not achieved. Pelvic exenteration is a possible treatment option for a selected group of patients resulting in a mean survival of nearly two years, offering a substantial prognostic improvement.

Although few patients will benefit from local treatment (stereotactic body radiation therapy or resection) after a recurrence involving the lung, local therapies might be considered as an option in oligometastatic lung recurrences as they achieve high local control rates and better oncological outcomes than systemic treatment alone.

VCB as monotherapy or in combination with EBRT in patients with FIGO II EAC was associated with improved survival. Inclusion of adjuvant VCB maintains an important role in treating patients with FIGO II EAC.